Work

HAIC plus TAE combined with tislelizumab and surufatinib in unresectable intrahepatic cholangiocarcinoma: The REACH-01 trial.

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.4087

Authors: Kangshuai Li, Tiezhong Zhang, Qiang Gao, Dongxu Wang, Yi Liu, Hao Chen, Zhen-yu Shao, Weiwei Lv, Cuijuan Zhang, Yunfei Xu, Zongli Zhang

Institutions: Qilu Hospital of Shandong University, Shandong University

Language: English

Topic: Cholangiocarcinoma and Gallbladder Cancer Studies

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Key Technology Research and Development Program of Shandong

Award: G2588751117

OpenAlex ID: W4410816728

Cites:

Cited by: 2

Related to: 10